About: Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
Creator	Chen, Hsin-Wei Liu, Shih-Jen Yu, Guann-Yi Chen, Mei-Yu Chai, Kit Chiang, Chen-Yi Wu, Chiao-Chieh
Source	PMC
abstract	BACKGROUND: The emergence of Zika virus (ZV) in tropical and subtropical areas of the world has created an urgent need for vaccines against ZV. However, approved vaccines that prevent ZV infection are not available. To develop an effective vaccine against ZV infection, a lipidated form of ZV envelope protein domain III that possesses an intrinsic adjuvant property was rationally designed. Our goal was to examine the immunogenicity of recombinant lipidated ZV envelope protein domain III (rLZE3) and evaluate its potential as a vaccine candidate against ZV. METHODS: Recombinant ZV envelope protein domain III (rZE3) and rLZE3 were prepared with an Escherichia coli-based system. Dendritic cell surface marker expression and cytokine production upon stimulation were analyzed to evaluate the function of rLZE3. Neutralizing antibody capacities were evaluated using focus reduction neutralization tests after immunization. To investigate the protective immunity in immunized mice, serum samples collected from immunized mice were adoptively transferred into AG129 mice, and then viremia levels and survival times were examined after ZV challenge. RESULTS: rLZE3 alone but not rZE3 alone efficiently activated dendritic cells in vitro and was taken up by dendritic cells in vivo. Immunization of C57BL/6 mice with rLZE3 alone (without exogenous adjuvant) could induce ZV-specific neutralizing antibody responses. Furthermore, serum samples obtained from rLZE3-immunized mice provided protection as indicated by a reduction in viremia levels and prolongation of survival times after ZV challenge. CONCLUSION: These results indicate that rLZE3 is an excellent vaccine candidate and has great potential that should be evaluated in further preclinical studies.
has issue date	2020-04-14(xsd:dateTime)
bibo:doi	10.1186/s12929-020-00646-x
bibo:pmid	32290844
has license	cc-by
sha1sum (hex)	4f0d6c0601ae25bed9ab0680ba5076776f8512c8
schema:url	https://doi.org/10.1186/s12929-020-00646-x
resource representing a document's title	Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
has PubMed Central identifier	PMC7158147
has PubMed identifier	32290844
schema:publication	J Biomed Sci
resource representing a document's body	covid:4f0d6c0601ae25bed9ab0680ba5076776f8512c8#body_text
is schema:about of	named entity 'infection' named entity 'prevent' named entity 'Zika virus' named entity 'emergence' named entity 'Our' named entity 'protein domain' named entity 'VACCINES' named entity 'ADJUVANT' named entity 'GraphPad Prism' named entity 'sodium phosphate' named entity 'Vero' named entity 'bone marrow' named entity 'Vero' named entity 'mice' named entity 'serum samples' named entity 'neutralizing antibodies' named entity 'adjuvant' named entity 'QIAgen' named entity 'antigen' named entity 'antibody' named entity 'NdeI' named entity 'mice' named entity 'Flaviviridae' named entity 'mice' named entity 'Adjuvants' named entity 'LPS' named entity 'incubation' named entity 'specific immune response' named entity 'Japanese encephalitis' named entity 'IgG antibodies' named entity 'vaccine' named entity 'Taiwan' named entity 'lymph nodes' named entity 'N-terminal' named entity 'serum samples' named entity 'Serum samples' named entity 'recombinant' named entity 'IMAC' named entity 'PBS' named entity 'arthralgia' named entity 'Bone marrow' named entity 'sucrose' named entity 'C57BL/6' named entity 'flow cytometry' named entity 'mice' named entity 'mice' named entity 'dialyzed' named entity 'saturated solution' named entity 'immunizations' named entity 'lymph nodes' named entity 'recombinant protein' named entity 'vaccination' named entity 'cell lysate' named entity 'antibodies' named entity 'virus' named entity 'mice' named entity 'passive transfer' named entity 'ADE' named entity 'dengue virus' named entity 'E. coli' named entity 'mice' named entity 'mannitol' named entity 'C57BL/6' named entity 'antibody' named entity '37°C' named entity 'digestion' named entity 'vaccine' named entity 'dengue' named entity 'dengue' named entity 'protein domain' named entity 'horseradish peroxidase' named entity 'self-limiting' named entity 'Limulus amebocyte lysate' named entity 'genus' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software